UB Paderborn / Katalog / Suche / in CDI

Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR)

The Journal of urology, 2021-05, Vol.205 (5), p.1421-1429

2021

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study

Drugs & aging, 2021-02, Vol.38 (2), p.137-146

2021

Link zum Volltext

Verfügbarkeit prüfen

Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial

International journal of clinical practice (Esher), 2022-04, Vol.2022, p.6475014-9

2022

Link zum Volltext

Verfügbarkeit prüfen

A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis

PloS one, 2015-11, Vol.10 (11), p.e0142081-e0142081

2015

Link zum Volltext

Verfügbarkeit prüfen

Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial

The lancet respiratory medicine, 2017-02, Vol.5 (2), p.135-146

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison

Advances in therapy, 2021-11, Vol.38 (11), p.5452-5464

2021

Link zum Volltext

Verfügbarkeit prüfen

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

The Lancet (British edition), 2002-03, Vol.359 (9312), p.1121-1122

2002

Link zum Volltext

Verfügbarkeit prüfen

Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis

Drugs in context, 2022, Vol.11

2022

Link zum Volltext

Verfügbarkeit prüfen

Population Pharmacokinetic/Pharmacodynamic Analysis of Intravenous Zanamivir in Healthy Adults and Hospitalized Adult and Pediatric Subjects With Influenza

Clinical and translational science, 2020-01, Vol.13 (1), p.157-168

2020

Link zum Volltext

Verfügbarkeit prüfen

International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR

The Journal of urology, 2020-08, Vol.204 (2), p.101097JU0000000000000807-324

2020

Link zum Volltext

Verfügbarkeit prüfen

Once-Daily versus Twice-Daily Lamivudine, in Combination with Zidovudine and Efavirenz, for the Treatment of Antiretroviral-Naive Adults with HIV Infection: A Randomized Equivalence Trial

Clinical infectious diseases, 2004-08, Vol.39 (3), p.411-418

2004

Link zum Volltext

Verfügbarkeit prüfen

Emergence of Resistance to Protease Inhibitor Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients: Selection of Four Alternative Viral Protease Genotypes and Influence of Viral Susceptibility to Coadministered Reverse Transcriptase Nucleoside Inhibitors

Antimicrobial Agents and Chemotherapy, 2002-03, Vol.46 (3), p.731-738

2002

Link zum Volltext

Verfügbarkeit prüfen

Reply by Authors

The Journal of urology, 2021-05, Vol.205 (5), p.1429-1429

2021

Link zum Volltext

Verfügbarkeit prüfen

Reply by Authors

The Journal of urology, 2020-08, Vol.204 (2), p.324-324

2020

Link zum Volltext

Verfügbarkeit prüfen

Vibegron improves quality‐of‐life measures in patients with overactive bladder: Patient‐reported outcomes from the EMPOWUR study

International journal of clinical practice (Esher), 2021-05, Vol.75 (5), p.e13937-n/a

2021

Link zum Volltext

Verfügbarkeit prüfen

PD21-02 EFFICACY OF ONCE-DAILY VIBEGRON 75 MG FOR OVERACTIVE BLADDER (OAB) IN OLDER PATIENTS: THE EMPOWUR RANDOMIZED, INTERNATIONAL, PHASE 3 STUDY

The Journal of urology, 2020-04, Vol.203, p.e453-e454

2020

Link zum Volltext

Verfügbarkeit prüfen

PD21-01 ONCE-DAILY VIBEGRON 75 MG FOR OVERACTIVE BLADDER (OAB): DOUBLE-BLIND 52-WEEK RESULTS FROM AN EXTENSION STUDY OF THE INTERNATIONAL PHASE 3 TRIAL (EMPOWUR)

The Journal of urology, 2020-04, Vol.203, p.e453

2020

Link zum Volltext

Verfügbarkeit prüfen

Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States

AIDS research and human retroviruses, 2018-08, Vol.34 (8), p.672

2018

Link zum Volltext

Verfügbarkeit prüfen

MP63-15 VIBEGRON FOR THE TREATMENT OF PATIENTS WITH DRY OVERACTIVE BLADDER: A SUBGROUP ANALYSIS FROM THE EMPOWUR TRIAL

The Journal of urology, 2021-09, Vol.206 (Supplement 3)

2021

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: Results of a randomized, double‐blind, placebo‐controlled phase 2 trial

Neurogastroenterology and motility, 2022-12, Vol.34 (12), p.e14448-n/a

2022

Link zum Volltext

Verfügbarkeit prüfen

Intravenous Zanamivir in Hospitalized Patients With Influenza

Pediatrics (Evanston), 2017-11, Vol.140 (5)

2017

Link zum Volltext

Verfügbarkeit prüfen

Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR

Advances in therapy, 2022-02, Vol.39 (2), p.959-970

2022

Link zum Volltext

Verfügbarkeit prüfen

Reply by Authors

The Journal of urology, 2021-05, Vol.205 (5), p.1429-1429

2021

Link zum Volltext

Verfügbarkeit prüfen

Reply by Authors

The Journal of urology, 2021-05, Vol.205 (5), p.1429

2021

Link zum Volltext

Verfügbarkeit prüfen

Reply by Authors

The Journal of urology, 2020-08, Vol.204 (2), p.324-324

2020

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR)

Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study

Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial

A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis

Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial

Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis

Population Pharmacokinetic/Pharmacodynamic Analysis of Intravenous Zanamivir in Healthy Adults and Hospitalized Adult and Pediatric Subjects With Influenza

International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR

Once-Daily versus Twice-Daily Lamivudine, in Combination with Zidovudine and Efavirenz, for the Treatment of Antiretroviral-Naive Adults with HIV Infection: A Randomized Equivalence Trial

Emergence of Resistance to Protease Inhibitor Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients: Selection of Four Alternative Viral Protease Genotypes and Influence of Viral Susceptibility to Coadministered Reverse Transcriptase Nucleoside Inhibitors

Reply by Authors

Reply by Authors

Vibegron improves quality‐of‐life measures in patients with overactive bladder: Patient‐reported outcomes from the EMPOWUR study

PD21-02 EFFICACY OF ONCE-DAILY VIBEGRON 75 MG FOR OVERACTIVE BLADDER (OAB) IN OLDER PATIENTS: THE EMPOWUR RANDOMIZED, INTERNATIONAL, PHASE 3 STUDY

PD21-01 ONCE-DAILY VIBEGRON 75 MG FOR OVERACTIVE BLADDER (OAB): DOUBLE-BLIND 52-WEEK RESULTS FROM AN EXTENSION STUDY OF THE INTERNATIONAL PHASE 3 TRIAL (EMPOWUR)

Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States

MP63-15 VIBEGRON FOR THE TREATMENT OF PATIENTS WITH DRY OVERACTIVE BLADDER: A SUBGROUP ANALYSIS FROM THE EMPOWUR TRIAL

Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: Results of a randomized, double‐blind, placebo‐controlled phase 2 trial

Intravenous Zanamivir in Hospitalized Patients With Influenza

Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR

Reply by Authors

Reply by Authors

Reply by Authors

Suchergebnisse filtern